Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Bought by Headlands Technologies LLC

Headlands Technologies LLC grew its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RAREFree Report) by 50.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,351 shares of the biopharmaceutical company’s stock after purchasing an additional 1,127 shares during the quarter. Headlands Technologies LLC’s holdings in Ultragenyx Pharmaceutical were worth $119,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Lazard Asset Management LLC raised its holdings in Ultragenyx Pharmaceutical by 36.6% in the first quarter. Lazard Asset Management LLC now owns 896 shares of the biopharmaceutical company’s stock valued at $64,000 after acquiring an additional 240 shares in the last quarter. Signaturefd LLC raised its holdings in Ultragenyx Pharmaceutical by 42.6% during the second quarter. Signaturefd LLC now owns 1,021 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 305 shares in the last quarter. American International Group Inc. raised its holdings in Ultragenyx Pharmaceutical by 36.3% during the second quarter. American International Group Inc. now owns 1,257 shares of the biopharmaceutical company’s stock worth $58,000 after purchasing an additional 335 shares in the last quarter. Treasurer of the State of North Carolina raised its holdings in Ultragenyx Pharmaceutical by 1.2% during the second quarter. Treasurer of the State of North Carolina now owns 29,553 shares of the biopharmaceutical company’s stock worth $1,363,000 after purchasing an additional 360 shares in the last quarter. Finally, Arizona State Retirement System raised its holdings in Ultragenyx Pharmaceutical by 2.2% during the second quarter. Arizona State Retirement System now owns 19,722 shares of the biopharmaceutical company’s stock worth $910,000 after purchasing an additional 425 shares in the last quarter. Hedge funds and other institutional investors own 96.37% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. StockNews.com raised shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a report on Friday, December 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $114.00 target price on shares of Ultragenyx Pharmaceutical in a report on Friday, January 19th. Morgan Stanley cut their target price on shares of Ultragenyx Pharmaceutical from $90.00 to $84.00 and set an “overweight” rating on the stock in a report on Friday, November 3rd. Wells Fargo & Company assumed coverage on shares of Ultragenyx Pharmaceutical in a report on Friday, December 8th. They issued an “overweight” rating and a $72.00 target price on the stock. Finally, Piper Sandler cut their target price on shares of Ultragenyx Pharmaceutical from $135.00 to $130.00 and set an “overweight” rating on the stock in a report on Wednesday, October 25th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $90.60.

Check Out Our Latest Research Report on Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Trading Up 2.8 %

NASDAQ:RARE opened at $46.73 on Monday. The firm’s fifty day moving average price is $45.38 and its 200 day moving average price is $40.03. Ultragenyx Pharmaceutical Inc. has a 1-year low of $31.52 and a 1-year high of $54.98.

Ultragenyx Pharmaceutical Company Profile

(Free Report)

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

Further Reading

Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc. (NASDAQ:RAREFree Report).

Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.